Published in J Psychiatr Res on April 26, 1995
Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag (2007) 1.26
The glial growth factors deficiency and synaptic destabilization hypothesis of schizophrenia. BMC Psychiatry (2002) 1.09
Use of atypical antipsychotics in the elderly: a clinical review. Clin Interv Aging (2014) 0.98
The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology (Berl) (2006) 0.90
Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br J Clin Pharmacol (2001) 0.87
Quetiapine reduces nocturnal urinary cortisol excretion in healthy subjects. Psychopharmacology (Berl) (2004) 0.84
Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study. Ther Adv Psychopharmacol (2011) 0.82
Sulpiride-induced hyperprolactinemia in mature female rats: evidence for alterations in the reproductive system, pituitary and ovarian hormones. Int J Fertil Steril (2014) 0.78
Hyperprolactinaemia with amisulpride. Indian J Psychiatry (2008) 0.76
Ziprasidone decreases cortisol excretion in healthy subjects. Br J Clin Pharmacol (2005) 0.75
Effects of dopamine D2/D3 receptor antagonism on human planning and spatial working memory. Transl Psychiatry (2017) 0.75
Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science (1999) 7.54
Continuity and discontinuity of affective disorders and schizophrenia. Results of a controlled family study. Arch Gen Psychiatry (1993) 2.71
Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human gammadelta T cells in Escherichia coli. FEBS Lett (2001) 1.96
The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry (2004) 1.64
Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine. Pharmacopsychiatry (2003) 1.62
Schizoaffective disorder and affective disorders with mood-incongruent psychotic features: keep separate or combine? Evidence from a family study. Am J Psychiatry (1992) 1.56
The prescribing of psychotropic drugs by primary care physicians: an international collaborative study. J Clin Psychopharmacol (1999) 1.43
Therapeutic drug monitoring in psychiatry. Pharmacopsychiatry (2011) 1.39
[Psychiatric diseases and their treatment in general practice in Germany. Results of a World Health Organization (WHO) study]. Nervenarzt (1996) 1.38
Differential stimulation of the Na+/H+ exchanger determines chloroquine uptake in Plasmodium falciparum. J Cell Biol (1998) 1.31
LytB, a novel gene of the 2-C-methyl-D-erythritol 4-phosphate pathway of isoprenoid biosynthesis in Escherichia coli. FEBS Lett (2001) 1.27
GcpE is involved in the 2-C-methyl-D-erythritol 4-phosphate pathway of isoprenoid biosynthesis in Escherichia coli. J Bacteriol (2001) 1.21
Strain differences in open-field and elevated plus-maze behavior of rats without and with pretest handling. Pharmacol Biochem Behav (1998) 1.19
Diaryl ester prodrugs of FR900098 with improved in vivo antimalarial activity. Bioorg Med Chem Lett (2001) 1.18
CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther (2006) 1.16
Tools for discovery of inhibitors of the 1-deoxy-D-xylulose 5-phosphate (DXP) synthase and DXP reductoisomerase: an approach with enzymes from the pathogenic bacterium Pseudomonas aeruginosa. FEMS Microbiol Lett (2000) 1.05
Moderate and severe depression. Gradations for the Montgomery-Asberg Depression Rating Scale. J Affect Disord (2000) 0.99
Radiation effects on plasma electron-spin-resonance (ESR) spectra of cancer patients. Radiology (1972) 0.99
Psychosocial stress in tree shrews: clomipramine counteracts behavioral and endocrine changes. Pharmacol Biochem Behav (1996) 0.99
Expression of var genes located within polymorphic subtelomeric domains of Plasmodium falciparum chromosomes. Mol Cell Biol (1997) 0.98
Panic disorder in patients with dizziness. Arch Intern Med (1994) 0.97
Clinical subtypes in panic disorder: their descriptive and prospective validity. J Affect Disord (1987) 0.97
Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology (Berl) (1998) 0.96
[[1]Benzothieno[3,2-b]pyridin-4-yl-amine--synthesis and investigation of activity against malaria]. Pharmazie (2004) 0.96
Distribution of clozapine and desmethylclozapine between blood and brain in rats. Eur Neuropsychopharmacol (1999) 0.94
Adenosinergic modulation of homocysteine-induced seizures in mice. Epilepsia (1990) 0.94
Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol (1998) 0.93
Operational diagnosis of endogenous depression. II. Comparison of 8 different operational diagnoses. Psychopathology (1985) 0.92
Chronic psychosocial stress and antidepressant treatment in tree shrews: time-dependent behavioral and endocrine effects. Neurosci Biobehav Rev (1999) 0.92
Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol (1998) 0.92
The HTR1B 861G>C receptor polymorphism among patients suffering from alcoholism, major depression, anxiety disorders and narcolepsy. Psychiatry Res (2000) 0.92
The Calgary Depression Rating Scale for Schizophrenia: development and interrater reliability of a German version (CDSS-G). J Psychiatr Res (1999) 0.90
Influence of splenectomy on first set rejection reactions of C57BL/6 females to male skin isografts. J Exp Med (1977) 0.89
Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging. Pharmacopsychiatry (2011) 0.89
The primary care evaluation of mental disorders (PRIME-MD), German version: a comparison with the CIDI. J Psychiatr Res (2000) 0.88
CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. Pharmacogenetics (1997) 0.87
Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol Psychiatry (1999) 0.87
Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high-performance liquid chromatography with ultraviolet detection. J Chromatogr (1992) 0.87
Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia. Br J Psychiatry (1999) 0.87
Seeking new targets for antiparasitic agents. Trends Parasitol (2001) 0.86
The role of cytochrome P450 2D6 in the metabolism of moclobemide. Eur Neuropsychopharmacol (1996) 0.86
Decreased benzodiazepine receptor binding in panic disorder measured by IOMAZENIL-SPECT. A preliminary report. Eur Arch Psychiatry Clin Neurosci (1994) 0.86
Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin Pharmacol Ther (2000) 0.86
Paroxetine serum concentrations in depressed patients and response to treatment. Pharmacopsychiatry (2005) 0.86
Acute, subchronic and discontinuation effects of zopiclone on sleep EEG and nocturnal melatonin secretion. Eur Neuropsychopharmacol (1996) 0.85
Stupor and affective state: alleviation of psychomotor disturbances by lorazepam and recurrence of symptoms after Ro 15-1788. J Nerv Ment Dis (1987) 0.85
The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions. Pharmacopsychiatry (2012) 0.85
Agomelatine and hepatotoxicity: implications of cumulated data derived from spontaneous reports of adverse drug reactions. Pharmacopsychiatry (2013) 0.84
[Regional therapy breast cancer liver metastases]. Zentralbl Chir (1995) 0.84
Therapeutic drug monitoring in Italian psychiatry. Pharmacopsychiatry (2011) 0.84
Extrapyramidal symptoms and their relationship to clinical efficacy under perphenazine treatment. A controlled prospective handwriting-test study in 22 acutely ill schizophrenic patients. Pharmacopsychiatry (1991) 0.84
Analysis of sleep EEG microstructure in subchronic paroxetine treatment of healthy subjects. Psychopharmacology (Berl) (1997) 0.83
Interleukin-6 in plasma collected with an indwelling cannula reflects local, not systemic, concentrations. Clin Chem (1994) 0.83
Dopamine, noradrenaline and 5-hydroxy-tryptamine in relation to motor activity, fighting and mounting behavior. I. L-dopa and DL-threo-dihydroxyphenylserine in combination with Ro 4-4602, pargyline and reserpine. Neuropharmacology (1973) 0.83
[Isoprenoid pigments in representatives of the family Microbacteriaceae]. Mikrobiologiia (2005) 0.82
Subchronic effects of olanzapine on sleep EEG in schizophrenic patients with predominantly negative symptoms. Pharmacopsychiatry (2004) 0.82
Identification of minor affective disorders and implications for psychopharmacotherapy. J Affect Disord (1991) 0.82
Lorazepam for a short-term alleviation of mutism. J Clin Psychopharmacol (1986) 0.82
Psychopharmacological drugs as represented in the press: results of systematic analysis of newspapers and popular magazines. Pharmacopsychiatry (1996) 0.82
Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology (Berl) (1994) 0.82
Inhibition of dextromethorphan metabolism by moclobemide. Psychopharmacology (Berl) (1998) 0.82
Susceptibility of chicken embryos to group A streptococci: correlation with fibrinogen binding. FEMS Immunol Med Microbiol (1993) 0.82
Sexual impotence: a double-blind study of LHRH nasal spray versus placebo. Neuropsychobiology (1975) 0.82
Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit (2001) 0.82
Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol (1994) 0.82
Stimulation of immediate early gene expression by desipramine in rat brain. Biol Psychiatry (1997) 0.82
Doxepin and its metabolites in plasma and cerebrospinal fluid in depressed patients. Psychopharmacology (Berl) (1997) 0.81
Depressive factors and their relationships with other symptom domains in schizophrenia, schizoaffective disorder, and psychotic depression. Schizophr Bull (2001) 0.81
Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). J Neural Transm (Vienna) (2005) 0.81
Lorazepam for treatment of catatonic symptoms and severe psychomotor retardation. Am J Psychiatry (1988) 0.81
Differential effects of high-dose amisulpride versus flupentixol on latent dimensions of depressive and negative symptomatology in acute schizophrenia: an evaluation using confirmatory factor analysis. Int Clin Psychopharmacol (2002) 0.81
Occupancy of striatal D(2)-like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic. Psychopharmacology (Berl) (1999) 0.81
[Dementia screening in routine clinical practice. A comparative analysis of MMSE, SIDAM and ADAS]. Nervenarzt (1998) 0.81
[Pyrido [3,2-b]indol-4-yl-amines--synthesis and investigation of activity against malaria]. Pharmazie (2004) 0.81
Psychological distress and psychiatric disorders in primary health care patients in East and West Germany 1 year after the fall of the Berlin Wall. Soc Psychiatry Psychiatr Epidemiol (1999) 0.81
Diazepam has no beneficial effects on stress-induced behavioural and endocrine changes in male tree shrews. Pharmacol Biochem Behav (2000) 0.81
Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice. Pharmacopsychiatry (2005) 0.81
Effects of subchronic paroxetine administration on night-time endocrinological profiles in healthy male volunteers. Psychoneuroendocrinology (2000) 0.81
Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial. Psychiatry Res (1999) 0.80
[Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring]. Fortschr Neurol Psychiatr (2001) 0.80
Increase in serum clomipramine concentrations caused by valproate. J Clin Psychopharmacol (2000) 0.80
Studies on pituitary hormones and releasing hormones in depression and sexual impotence. Prog Brain Res (1975) 0.80
Combination of open field and elevated plus-maze: a suitable test battery to assess strain as well as treatment differences in rat behavior. Prog Neuropsychopharmacol Biol Psychiatry (1998) 0.80
Pharmacokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application. Psychopharmacology (Berl) (1994) 0.80
Steady state concentrations of clomipramine and its major metabolite desmethylclomipramine in rat brain and serum after oral administration of clomipramine. Eur Neuropsychopharmacol (2000) 0.80
Preferential uptake of norepinephrine into dopaminergic terminals of a synaptosomal preparation from rat cerebral cortex. Brain Res (1984) 0.80
Effects of pulsed high-frequency electromagnetic fields on the neuroendocrine system. Neuroendocrinology (1998) 0.80
Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J Clin Psychopharmacol (2001) 0.80
[Critical comments on the methods of assessing the effectiveness of antidepressive pharmacotherapy]. Nervenarzt (1987) 0.80
Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats. J Neural Transm (Vienna) (2002) 0.80
Influence of hydrocoritsone and glucagon on liver tyrosine transaminase and on brain tyrosine, norepinephrine and serotonin. Nature (1970) 0.80
Chronic oral haloperidol and clozapine in rats: A behavioral evaluation. Neuropsychobiology (1999) 0.80
L-dopa plus decarboxylase inhibitor in depression. Lancet (1970) 0.80
Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. J Clin Psychiatry (1996) 0.80
[Standardized documentation procedure as a basis for improvement of process quality of treatment in psychiatric hospitals]. Nervenarzt (2003) 0.79